Drug intelligence / Profile preview

cathepsin B siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous
01

Overview

Cathepsin B siRNA is a small interfering RNA (siRNA) designed to specifically target and silence the expression of the cathepsin B (CTSB) gene. Cathepsin B is a lysosomal cysteine protease involved in various physiological and pathological processes, including protein degradation, apoptosis, and inflammation. By utilizing the RNA interference (RNAi) pathway, the siRNA facilitates the degradation of CTSB mRNA, leading to a significant reduction in cathepsin B protein levels. In preclinical research, such as studies on cerebral aneuryses, silencing cathepsin B has been shown to mitigate the apoptosis of vascular smooth muscle cells (VSMCs) by inhibiting the activation of Caspase-3 and modulating signaling pathways like JNK. This approach is being explored for its potential therapeutic benefits in diseases characterized by excessive cathepsin B activity, including certain cancers and vascular disorders.

Other names
siRNA targeting cathepsin BCTSB siRNAcathepsin B small interfering RNA
02

Targets

CTSB (Cathepsin B)

Beyond the preview

Go deeper on cathepsin B siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cathepsin B siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call